AACR 2024: Generation of humanized PD-1/PD-L1/CD94/NKG2A mice for evaluating novel combination therapies
Used in the poster: B-hPD-1/hPD-L1/hCD94/hNKG2A mice
Summary:
We created a quadruple humanized mouse model expressing NKG2A, CD94, PD-1, and PD-L1 to investigate potential combination therapies. Flow cytometry confirmed expression of these targets on immune cells. In vivo testing with antibodies targeting NKG2A and PD-L1 showed that combination therapy significantly reduced tumor growth compared to NKG2A single antibody treatment. These findings validate the humanized mouse model for further evaluation of combination therapies.
